Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: Analysis of the Phase III Double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II Studies

Authors
Category Primary study
JournalSwiss Medical Weekly
Year 2016
This article has no abstract
Epistemonikos ID: 9190c9f3a03091d35f2f2252307372819021d1d8
First added on: Feb 10, 2025